Thus, improving tumor immunosuppressive microenvironment and simultaneously expanding the population of CD8+ T cells, especially stem-like CD8+ T cells with an APC niche in tumor tissues, might be a viable strategy for enhancing the response to anti-PD-1 antibody in HCC therapy. The gene discussed is CD8A; the disease is neoplasm.